Extended Viewer
Antibiotic Resistance and What is ESG?
18 mins listen December 17, 2021
Antibiotic resistance is more worrisome than ever. It is possible that by 2050, three times as many people could die a year as died during the worst parts of the COVID-19 pandemic. But there may be hope in the development of novel antibiotics. We discuss how this is related to the development of the COVID-19 vaccine. Then we finally put ESG ratings in their rightful place and tell you what they are REALLY used for.
Featuring
Laura Nishikawa
Managing Director, ESG Research
Julia Giguere-Morello
ESG Researcher, MSCI
Related content
ESG Now Podcast
ESG explored. A rotating cast of researchers on environmental, social, and governance issues join hosts Mike Disabato and Bentley Kaplan as they discuss the most pressing news of the week. But in an enjoyable way.
Previous EpisodesPutting ESG Ratings in Their Rightful Place
An ESG rating provides only one lens — a financial relevance lens that zooms in on questions of business resilience. That means answering other questions requires using other lenses.
Learn More